Effects of TP53 mutational status on gene expression patterns across 10 human cancer types

Journal of Pathology

Volumn 232, Issue 5, 2014, Pages 522-533

  Parikh, Neha ^a   Hilsenbeck, Susan ^a   Creighton, Chad J ^a   Dayaram, Tajhal ^a   Shuck, Ryan ^a   Shinbrot, Eve ^a   Xi, Liu ^a   Gibbs, Richard A ^a   Wheeler, David A ^a   Donehower, Lawrence A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

CDKN1A; E2F1; FOXM1; MYBL2; nonsense mediated mRNA decay; p53; RPS27Li; TCGA; TP53; ZMAT3

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; MESSENGER RNA; PROTEIN MDM2; PROTEIN P53; PUMA PROTEIN; RNA POLYMERASE II; TRANSCRIPTION FACTOR E2F1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; ARTICLE; BLADDER CARCINOMA; BREAST CARCINOMA; CANCER CELL CULTURE; CELL CYCLE S PHASE; COLORECTAL CARCINOMA; CYSTADENOCARCINOMA; DIPLOIDY; ENDOMETRIUM CARCINOMA; FEMALE; FRAMESHIFT MUTATION; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE REPRESSION; GENE TARGETING; GENOMICS; GENOTYPE; GLIOBLASTOMA; GLIOMA; HAPLOIDY; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MULTIPLE CANCER; NONSENSE MEDIATED MRNA DECAY; NONSENSE MUTATION; PRIORITY JOURNAL; REGULATOR GENE; RNA SEQUENCE; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; TRANSCRIPTOMICS; TUMOR GROWTH; UPREGULATION; UTERINE CORPUS ENDOMETRIOID CARCINOMA;

CDKN1A; E2F1; FOXM1; MYBL2; NONSENSE-MEDIATED MRNA DECAY; P53; RPS27LI; TCGA; TP53; ZMAT3;

CELL CYCLE PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; MUTATION; NEOPLASMS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84895926637     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4321     Document Type: Article

References (35)

1. Vousden KH, Prives C,. Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413-431.
2. Petitjean A, Achatz MI, Borresen-Dale AL, et al., TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26: 2157-2165.
3. Soussi T., TP53 mutations in human cancer: database reassessment and prospects for the next decade. Adv Cancer Res 2011; 110: 107-139.
4. Cancer Genome Atlas Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068.
5. Cancer Genome Atlas Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
6. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
7. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337.
8. Cancer Genome Atlas Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-525.
9. Riley T, Sontag E, Chen P, et al., Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9: 402-412.
10. Bornstein C, Brosh R, Molchadsky A, et al., SPATA18, a spermatogenesis-associated gene, is a novel transcriptional target of p53 and p63. Mol Cell Biol 2011; 31: 1679-1689.
11. Kawase T, Ohki R, Shibata T, et al., PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt. Cell 2009; 136: 535-550.
12. Nicholson P, Yepiskoposyan H, Metze S, et al., Nonsense-mediated mRNA decay in human cells: mechanistic insights, functions beyond quality control and the double-life of NMD factors. Cell Mol Life Sci 2010; 67: 677-700.
13. Kaeser MD, Iggo RD,. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci USA 2002; 99: 95-100.
14. DeGregori J, Johnson DG,. Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr Mol Med 2006; 6: 739-748.
15. Efeyan A, Murga M, Martinez-Pastor B, et al., Limited role of murine ATM in oncogene-induced senescence and p53-dependent tumor suppression. PLoS One 2009; 4: e5475.
16. Raychaudhuri P, Park HJ,. FoxM1: a master regulator of tumor metastasis. Cancer Res 2011; 71: 4329-4333.
17. Hestand MS, van Galen M, Villerius MP, et al., CORE-TF: a user-friendly interface to identify evolutionary conserved transcription factor binding sites in sets of co-regulated genes. BMC Bioinformat 2008; 9: 495.
18. Lo KC, Bailey D, Burkhardt T, et al., Comprehensive analysis of loss of heterozygosity events in glioblastoma using the 100K SNP mapping arrays and comparison with copy number abnormalities defined by BAC array comparative genomic hybridization. Genes Chromosomes Cancer 2008; 47: 221-237.
19. Gondek LP, Tiu R, O'Keefe CL, et al., Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008; 111: 1534-1542.
20. Saeki H, Kitao H, Yoshinaga K, et al., Copy-neutral loss of heterozygosity at the p53 locus in carcinogenesis of esophageal squamous cell carcinomas associated with p53 mutations. Clin Cancer Res 2011; 17: 1731-1740.
21. Baker SJ, Fearon ER, Nigro JM, et al., Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989; 244: 217-221.
22. Troester MA, Herschkowitz JI, Oh DS, et al., Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 2006; 6: 276.
23. 2/M transcription. EMBO J 2004; 23: 4615-4626.
24. Laoukili J, Kooistra MR, Bras A, et al., FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005; 7: 126-136.
25. Sahin E, Depinho RA,. Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature 464: 520-528.
26. -/- multipotent progenitors. Nature 2008; 453: 228-232.
27. Sadasivam S, Duan S, DeCaprio JA,. The MuvB complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expression. Genes Dev 2012; 26: 474-489.
28. Polager S, Ginsberg D,. p53 and E2f: partners in life and death. Nat Rev Cancer 2009; 9: 738-748.
29. Incassati A, Patel D, McCance DJ,. Induction of tetraploidy through loss of p53 and upregulation of Plk1 by human papillomavirus type-16 E6. Oncogene 2006; 25: 2444-2451.
30. McKenzie L, King S, Marcar L, et al., p53-dependent repression of polo-like kinase-1 (PLK1). Cell Cycle 2010; 9: 4200-4212.
31. Scian MJ, Carchman EH, Mohanraj L, et al., Wild-type p53 and p73 negatively regulate expression of proliferation related genes. Oncogene 2008; 27: 2583-2593.
32. Yun J, Chae HD, Choy HE, et al., p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor. J Biol Chem 1999; 274: 29677-29682.
33. Barsotti AM, Prives C,. Pro-proliferative FoxM1 is a target of p53-mediated repression. Oncogene 2009; 28: 4295-4305.
34. Kalashnikova EV, Revenko AS, Gemo AT, et al., ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res 2010; 70: 9402-9412.
35. Musacchio A, Salmon ED,. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 2007; 8: 379-393.